The Vigabatrin REMS Program is required by the FDA to make sure informed risk-benefit decisions prior to initiating treatment, and to guarantee suitable use of vigabatrin while patients are treated. It is not feasible for your healthcare provider to know when vision loss will certainly occur.
It is advised that your healthcare provider examination your (or your kid's) vision before or within 4 weeks after beginning SABRIL and at least every 3 months during therapy till SABRIL is stopped. Tell your doctor if you or your kid have any adverse effects that bothers you or that does not go away.
Inform your healthcare provider if you are expectant or mean to get pregnant. If vision testing can not be done, your doctor might proceed prescribing SABRIL, but will not have the ability to watch for any type of vision loss. Your health care carrier may stop suggesting SABRIL for you (or your child)if vision examinations are not done consistently.